Denali Therapeutics Inc (NASDAQ:DNLI) Receives $28.17 Consensus PT from Analysts

Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have been given an average rating of “Buy” by the nine brokerages that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $27.14.

DNLI has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Denali Therapeutics in a report on Friday, December 20th. Wedbush initiated coverage on shares of Denali Therapeutics in a report on Wednesday, September 25th. They set a “neutral” rating and a $19.00 price target on the stock. They noted that the move was a valuation call. Finally, ValuEngine downgraded shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday.

In other news, insider Carole Ho sold 2,566 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $20.00, for a total value of $51,320.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Ryan J. Watts sold 42,185 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $18.02, for a total transaction of $760,173.70. Following the completion of the transaction, the chief executive officer now owns 12,505 shares in the company, valued at approximately $225,340.10. The disclosure for this sale can be found here. Insiders sold a total of 93,054 shares of company stock worth $1,695,673 in the last quarter. Company insiders own 21.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. BlackRock Inc. lifted its stake in shares of Denali Therapeutics by 13.3% in the 2nd quarter. BlackRock Inc. now owns 5,154,097 shares of the company’s stock worth $106,999,000 after purchasing an additional 604,766 shares during the period. Pictet Asset Management Ltd. lifted its stake in shares of Denali Therapeutics by 3.8% in the 3rd quarter. Pictet Asset Management Ltd. now owns 767,357 shares of the company’s stock worth $11,756,000 after purchasing an additional 28,009 shares during the period. Northern Trust Corp lifted its stake in shares of Denali Therapeutics by 1.0% in the 2nd quarter. Northern Trust Corp now owns 620,050 shares of the company’s stock worth $12,873,000 after purchasing an additional 6,063 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Denali Therapeutics by 4.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 353,122 shares of the company’s stock worth $7,331,000 after purchasing an additional 14,475 shares during the period. Finally, Citadel Advisors LLC raised its stake in Denali Therapeutics by 601.9% during the 2nd quarter. Citadel Advisors LLC now owns 194,876 shares of the company’s stock worth $4,045,000 after acquiring an additional 167,111 shares during the period. Hedge funds and other institutional investors own 73.62% of the company’s stock.

Shares of NASDAQ DNLI traded up $0.25 during trading on Friday, reaching $22.36. 677,942 shares of the company traded hands, compared to its average volume of 477,236. The firm has a 50 day simple moving average of $18.61 and a 200-day simple moving average of $18.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.59 and a current ratio of 10.59. Denali Therapeutics has a 52-week low of $14.24 and a 52-week high of $28.86.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.08. The firm had revenue of $13.60 million for the quarter, compared to the consensus estimate of $10.86 million. Denali Therapeutics had a negative net margin of 44.73% and a negative return on equity of 13.37%. As a group, analysts anticipate that Denali Therapeutics will post -2.02 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: Pattern Day Trader – What is the PDT Rule?

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.